This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
10/21/2024
Harry
Operator
Hello and welcome to the CASB KZ3Q&9M2024 Financial Results Conference Call. My name is Harry and I'll be your operator today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. To ask a question during Q&A, please use the raised hand button if you have joined via Zoom or dial star 1 if you're joining over the phone. I would now like to turn the call over to David Ferguson at CASB to begin. David, please go ahead when you're ready.
David Ferguson
Host / Moderator
Great. Thank you, Harry.
David Ferguson
Host / Moderator
Good afternoon. Good morning, everyone. Welcome to our third quarter nine month 2024 financial results. We'll also talk about our decision to acquire a controlling stake of Hep C, Barada. On the call, as usual, is our CEO and co-founder, Mikhail Lontardza, our CFO and Deputy CEO, Tengiz Mesidis, and Deputy CEO, Yuri Dedenko. I'm David Ferguson. We'll talk you through the presentation, Mikhail through the strategic updates, myself through the financials, then Mikhail We'll talk again about the Hep C Barada transaction. So on that note, I'll hand over to Mikhail. Mikhail, over to you.
You're reading a preview of the KSPI Q3 2024 earnings call.
Free account.
Disclaimer